Trending
- Merck Invests More Than € 300 Million in New Life Science Research Center in Germany
- Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
- Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
- Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-In-Class Oral MRGPR Antagonists
- Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
- Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease
- European Commission Approves Pfizer’s EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- TriLink BioTechnologies Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
Top Headlines
Merck, a leading science and technology company, is investing more than € 300 million in a new research center at…
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene…
Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and…
Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for…
Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177…
Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-In-Class…
Incyte and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small…
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved…
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare…
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and…
Featured Event
Clinical Trials
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration…
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the…
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to…
Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically…
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic…
PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the…
Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study…
Johnson & Johnson announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia…
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Repare Therapeutics Inc. announced that, under its worldwide license and collaboration agreement with Roche for the development and commercialization…
Fast shipping, security and absolute privacy is our main goal Viagra-Buy.com/ savings on their medication from a licensed and certified pharmacy.
The best pharmacy in america Viagra-Buy.com Fast delivery, best prices and for real men
Drug Research
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific…
AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and…
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of…
NeoImmuneTech, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Bayer and Recursion focus research collaboration on Oncology
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to…
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision…
Prelude Therapeutics Incorporated and AbCellera announced a multi-year, multi-program partnership to discover,…
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development…
AbCellera announced that it has entered into a strategic collaboration with Incyte to discover and develop…
Manufacturing
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of…
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that…
Astraveus awarded €10.4 million grant by the French government as part of France 2030…
Astraveus SAS, the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT)…
Samsung Biologics and Kurma Partners announce strategic partnership for development and…
Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of…
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of…
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind…
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO…
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee,…
Astellas Pharma Inc. announced its intention to submit a planning application to build a new state-of-the-art…
GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has ramped…
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., a global leader in generic and…
Diseases
SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation…
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to…
Kesin Pharma Announces FDA Approval and U.S. Availability of LIKMEZ (metronidazole) Oral…
Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose…
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss…
Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc., a clinical-stage biotechnology company dedicated to…
Ionis enters collaboration to advance next generation program targeting Lp(a) for…
Ionis Pharmaceuticals, Inc. announced that it has entered a collaboration and license agreement with Novartis for…
FDA Approves Merck’s ERVEBO (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of…
Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration…
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First…
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a…